RDY FY 2019 Earnings Report — Dr. Reddy's Laboratories Limited Revenue & Financial Results | Market Cap Arena

Dr. Reddy's Laboratories LimitedRDY

FY 2019 Earnings

Reported June 3, 2019

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2019	Prior Q	FY 2018	QoQ Change	YoY Change
Revenue	$1.6B	—	$1.5B	—	8.3%
Op. Income	$222M	—	$127M	—	75.3%
Gross Margin	54.2%	—	53.7%	—	0.5pp
Net Margin	12.2%	—	6.9%	—	5.3pp
EPS (Diluted)	$1.20	—	$0.63	—	91.6%
Free Cash Flow	$225M	—	$74M	—	203.7%

Revenue Flow

Item	Amount
REVENUE	$1.6B
Cost of Revenue	$748M
GROSS PROFIT	$886M
R&D Expenses	$166M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$519M
Other Expenses	-$7M
Operating Expenses	$664M
Cost & Expenses	$1.4B
OPERATING INCOME	$222M
Interest Income	$8M
Interest Expense	$9M
Other Income/Expenses	$17M
INCOME BEFORE TAX	$238M
Income Tax Expense	$39M
Net Income from Continuing Ops	$200M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$200M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$200M
D&A	$129M
EBIT	$248M
EBITDA	$377M
EPS	$1
EPS Diluted	$1

Income Statement

Item	Amount
REVENUE	$1.6B
Cost of Revenue	$748M
GROSS PROFIT	$886M
R&D Expenses	$166M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$519M
Other Expenses	-$7M
Operating Expenses	$664M
Cost & Expenses	$1.4B
OPERATING INCOME	$222M
Interest Income	$8M
Interest Expense	$9M
Other Income/Expenses	$17M
INCOME BEFORE TAX	$238M
Income Tax Expense	$39M
Net Income from Continuing Ops	$200M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$200M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$200M
D&A	$129M
EBIT	$248M
EBITDA	$377M
EPS	$1
EPS Diluted	$1

Cash Flow Statement

Item	Amount
Net Income	$200M
Depreciation & Amortization	$129M
Stock-Based Compensation	$4M
Deferred Income Tax	$39M
Other Non-Cash Items	-$6M
Change in Working Capital	-$61M
OPERATING CASH FLOW	$305M
Capital Expenditure	-$80M
Acquisitions (Net)	$6M
Purchases of Investments	-$834M
Sales/Maturities of Investments	$810M
Other Investing Activities	$16M
NET CASH FROM INVESTING	-$82M
Net Debt Issuance	-$161M
Common Stock Repurchased	-$6M
Common Dividends Paid	-$42M
Other Financing Activities	-$17M
NET CASH FROM FINANCING	-$226M
FREE CASH FLOW	$225M
Net Change in Cash	-$3M

Balance Sheet

Item	Amount
Cash & Equivalents	$24M
Short-Term Investments	$239M
Net Receivables	$495M
Inventory	$357M
Other Current Assets	$163M
TOTAL CURRENT ASSETS	$1.2B
PP&E (Net)	$574M
Goodwill	$41M
Intangible Assets	$471M
Long-Term Investments	$35M
Tax Assets	$44M
Other Non-Current Assets	$11M
TOTAL NON-CURRENT ASSETS	$1.2B
TOTAL ASSETS	$2.4B
Account Payables	$109M
Short-Term Debt	$173M
Deferred Revenue	$14M
Other Current Liabilities	$98M
TOTAL CURRENT LIABILITIES	$634M
Long-Term Debt	$228M
Deferred Revenue NC	$21M
Deferred Tax Liabilities	$6M
Other Non-Current Liabilities	$10M
TOTAL NON-CURRENT LIABILITIES	$271M
TOTAL LIABILITIES	$905M
Common Stock	$9M
Additional Paid-In Capital	$87M
Retained Earnings	$1.4B
Treasury Stock	-$6M
Accum. Other Comp. Income	$32M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$1.5B
Minority Interest	$0
TOTAL EQUITY	$1.5B
TOTAL LIABILITIES & EQUITY	$2.4B
Total Debt	$408M
Net Debt	$384M